Advice
The Marketing Authorisation for this product has been withdrawn
Medicine details
- Medicine name:
- Lumiracoxib 100mg tablets (Prexige®)
- SMC ID:
- 245/06
- Indication:
- Symptomatic relief in the treatment of osteoarthritis
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 13 March 2006
Additional notes
The marketing authorisation for lumiracoxib (Prexige) has been withdrawn
The European Medicines Agency (EMEA) has completed a review of the safety of medicines containing lumiracoxib. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of these medicines no longer outweigh their risks, and that all marketing authorisations should be withdrawn (revoked) throughout Europe.